Association between antihypertensive medications and hepatocellular carcinoma risk in individuals with metabolic dysfunction–associated steatotic liver disease (MASLD) without cirrhosis
Association between antihypertensive medications and hepatocellular carcinoma risk in individuals with metabolic dysfunction–associated steatotic liver disease (MASLD) without cirrhosis. // Annals of Thoracic Surgery Short Reports. – URL: https://www.sciencedirect.com/science/article/pii/S1665268126000529?dgcid=rss_sd_all
Association between antihypertensive medications and hepatocellular carcinoma risk in individuals with metabolic dysfunction–associated steatotic liver disease (MASLD) without cirrhosis. Annals of Thoracic Surgery Short Reports. https://www.sciencedirect.com/science/article/pii/S1665268126000529?dgcid=rss_sd_all
“Association between antihypertensive medications and hepatocellular carcinoma risk in individuals with metabolic dysfunction–associated steatotic liver disease (MASLD) without cirrhosis.” Annals of Thoracic Surgery Short Reports.
@article{article3475,
title = {Association between antihypertensive medications and hepatocellular carcinoma risk in individuals with metabolic dysfunction–associated steatotic liver disease (MASLD) without cirrhosis},
journal = {Annals of Thoracic Surgery Short Reports},
url = {https://www.sciencedirect.com/science/article/pii/S1665268126000529?dgcid=rss_sd_all}
}
Publication date: January–June 2027 Source: Annals of Hepatology, Volume 32, Issue 1 Author(s): Marie Louise N. Therkelsen, Liv Eline Hetland, Mikkel Parsberg Werge, Mira Thing, Elias Badal Rashu, Puria Nabilou, Nina Kimer, Anders...